Cite
MLA Citation
Dirk Schadendorf et al.. “Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma.” European journal of cancer, vol. 67, 2016, pp. 46–54. http://access.bl.uk/ark:/81055/vdc_100038226643.0x00003a